Search Results

You are looking at 101 - 110 of 825 items for :

  • Refine by Access: All x
Clear All
Full access

Chimeric Antigen Receptor T-Cell Therapy

Ndiya Ogba, Nicole M. Arwood, Nancy L. Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J. Fry, Morgan Garber, Rebecca A. Gardner, Lauren Gurschick, Patricia Kropf, Jeff J. Reitan, Craig Sauter, Bijal Shah, Elizabeth J. Shpall, and Steven T. Rosen

later. 4 , 11 , 12 CD19 CAR T-Cell Therapy and Disease Management Leukemias Prognosis and overall survival (OS) rates in adult and pediatric patients with relapsed and refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. 13 – 15

Full access

Chemotherapy in the Management of Osteosarcoma and Ewing's Sarcoma

Scott M. Schuetze

. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity . N Engl J Med 1986 ; 314 : 1600 – 1606 . 19. Rosen G Caparros B Huvos AG . Preoperative chemotherapy for osteogenic sarcoma

Full access

Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors

Jerald P. Radich and Vivian Oehler

phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse . Leukemia 2005 ; 19 : 507 – 512 . 21. Merx K Muller MC Kreil S . Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic

Full access

Advancements in Radiation Techniques for Gastric Cancer

Matthew D. Callister and Leonard L. Gunderson

early locoregional relapse and attempt surgical resection and salvage. Local disease relapse was seen in 67% of patients, and 88% of these had a component of local or regional failure. In addition, 50% of peritoneal failures were localized to the

Full access

Defining and Managing High-Risk Multiple Myeloma: Current Concepts

Luciano J. Costa and Saad Z. Usmani

7 molecular subgroups of NDMM, 9 3 of which were described as having the highest risk of early relapse: the MMSET gene overexpression, MAF / MAFB overexpression, and proliferative gene overexpression subgroups. The Arkansas group also developed

Full access

Use of Biomarkers and Multigene Assays in Breast Cancer

Lee S. Schwartzberg

, they can stratify patients into lower and higher risk of later relapse between years 5 through 10 after diagnosis. The Breast Cancer Index also appears to have some predictive value for prolonged endocrine therapy. As a fundamental change, the latest

Full access

Analysis of Circulating Tumor Cells in Breast Cancer

Zeynep Eroglu, Odicie Fielder, and George Somlo

Through coordinated scientific, medical, and public health advances, 5-year survival rates for breast cancer approach 90%. However, microscopic residual disease frequently results in local relapse or metastasis, leading to approximately 40

Full access

Novel Targets for Therapeutic Agents in Small Cell Lung Cancer

Patrick C. Ma and Ravi Salgia

. N901-blocked ricin for relapsed small-cell lung cancer . Chest 1993 ; 103 : 436S – 439S . 60 Lynch TJ Jr Lambert JM Coral F . Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin . J Clin Oncol 1997

Full access

Optimizing Endocrine Therapy for Breast Cancer

Amelia B. Zelnak and Ruth M. O'Regan

improved outcomes for patients with all stages of hormone receptor (HR)–positive breast cancer. However, despite the marked success of endocrine therapy in the treatment of HR-positive breast cancers, many patients will experience relapse and all patients

Full access

Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

investigators pooled estimates for distant metastases, visceral recurrences, and occurrence rate of locoregional relapses. Considering that treatment outcomes may vary among different types of bisphosphonates, the investigators performed subgroup analyses for